AIDS vaccine development: Perspectives, challenges & hopes

Indian Journal of Medical Research

Volumn 121, Issue 4, 2005, Pages 568-581

  Excler, Jean Louis ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VACCINE; BCG VACCINE; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RECOMBINANT VACCINE; SUBUNIT VACCINE; SYNTHETIC PEPTIDE; VACCINIA VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALPHA VIRUS; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POLITICS; PRIMARY PREVENTION; PROTECTION; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ISOLATION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; DRUG DESIGN; HIV INFECTIONS; HUMANS;

EID: 18844459354     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. UNAIDS. 2004 Report on the global AIDS epidemic. 4th Global Report.
2. Excler JL. HIV vaccine development in South-East Asia. In: Narain JP, editor. AIDS in Asia - The challenge ahead. New Delhi: SAGE; 2004 p. 360-73.
3. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355 : 2061-6.
4. Simoes EA, Babu PG, John TJ, Nirmala S, Solomon S, Lakshminarayana CS, et al. Evidence for HTLV-III infection in prostitutes in Tamil Nadu (India). India J Med Res 1987; 85 : 335-8.
5. www.naco.nic.in
6. Mehendale SM, Rodrigues JJ, Brookmeyer RS, Gangakhedkar RR, Divekar AD, Gokhale MR, et al. Incidence and predictors of human immunodeficiency virus type 1 seroconversion in patients attending sexually transmitted disease clinics in India. J Infect Dis 1995; 172 : 1486-91.
7. Mehendale SM, Shepherd ME, Divekar AD, Gangakhedkar RR, Kamble SS, Menon PA, et al. Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Indian J Med Res 1996; 104 : 327-35.
8. Gangakhedkar RR, Bentley ME, Divekar AD, Gadkari D, Mehendale SM, Shepherd ME, et al. Spread of HIV infection in married monogamous women in India. JAMA. 1997; 278 : 2090-2.
9. Bollinger RC, Brookmeyer RS, Mehendale SM, Paranjape RS, Shepherd ME, Gadkari DA, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997: 278 : 2085-9.
10. McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS 2000; 14 (Suppl 3) : S31-4.
11. Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 2000; 74 : 11286-95.
12. Tovanabutra S, Polonis V, De Souza M, Trichavaroj R, Chanbancherd P, Kim B, et al. First CRF01Æ/B recombinant of HIV-1 is found in Thailand. AIDS 2001; 15 : 1063-5.
13. McCutchan FE, Viputtigul K, de Souza MS, Carr JK, Markowitz LE, Buapunth P, et al. Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. AIDS Res Hum Retroviruses 2000; 16 : 801-5.
14. Porter KR, Mascola JR, Hupudio H, Ewing D, VanCott TC, Anthony RL, et al. Genetic, antigenic and serologic characterisation of human immunodeficiency virus type 1 from Indonesia. J AIDS 1997; 14 : 1-6.
15. Yu XF, Wang X, Mao P, Wang S, Li Z, Zhang J, et al. Characterization of HIV type 1 heterosexual transmission in Yunnan, China. AIDS Res Hum Retroviruses 2003; 19 : 1051-5.
16. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Kostler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 2000; 74 : 11367-76.
17. Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 2000; 14 : 75-83.
18. Motumura K, Kusagawa S, Kato K, Nohtomi K, Lwin HH, Tun KM. Emergence of new forms of human deficiency virus type 1 intersubtype recombinants in central Myanmar. AIDS Res Hum Retroviruses 2000; 16 : 1831-43.
19. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. WHO-UNAIDS network for HIV isolation and characterisation. Estimated global distribution and regional spread of HIV-1 genetic sub-types in the year 2000. J AIDS 2002; 29 : 184-90.
20. Mandal D, Jana S, Panda S, Bhattacharya S, Ghosh TC, Bhattacharya SK, et al. Distribution of HIV-1 subtypes in female sex workers of Calcutta, India. Indian J Med Res 2000; 112 : 165-72.
21. Chakrabarti S, Panda S, Chatterjee A, Sarkar S, Manna B, Singh NB, et al. HIV-1 subtypes in injecting drug users & their non-injecting wives in Manipur, India. Indian J Med Res 2000; 111 : 189-94.
22. Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, Bollinger RC. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998; 107 : 1-9.
23. Halani N, Wang B, Ge YC, Ghapure H, Hira S, Saksena NK. Changing epidemiology of HIV type 1 infections in India: Evidence of subtype B introduction in Bombay from a common source. AIDS Res Hum Retroviruses 2001; 17 : 637-42.
24. Sahni AK, Prasad VV, Seth P. Genomic diversity of human immunodeficiency virus type-1 in India. Int J STD AIDS 2002; 13 : 115-8.
25. Tripathy S, Renjifo B, Wang WK, McLane MF, Bollinger R, Rodrigues J, et al. Envelope glycoprotein 120 sequences of primary HIV type 1 isolates from Pune and New Delhi, India. AIDS Res Hum Retroviruses 1996; 12 : 1199-202.
26. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73 : 152-60.
27. Nathanson N, Mathieson BJ. Biological considerations in the development of human immunodeficiency virus vaccine. J Infect Dis 2000; 182 : 579-89.
28. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998; 280 : 1875-80.
29. Burton D, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nature Immunol 2004; 5 : 233-6.
30. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nature Med 2003; 9 : 861-6.
31. Blattner WA, Ann Oursler K, Cleghorn F, Charurat M, Sill A, Bartholomew C, et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004; 189: 1793-801.
32. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189 : 1785-92.
33. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nature Med 2004; 10 : 275-81.
34. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Med 2004; 10 : 282-9.
35. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 2004; 18 : 1489-93.
36. Emini EA, Koff WC. Developing an AIDS Vaccine: Need, Uncertainty, Hope. Science 2004; 304 : 1913-4.
37. Desrosiers RC. Prospects for an AIDS vaccine. Nature Med 2004; 10 : 221-3.
38. Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3 : 217-28.
39. Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: Summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS). J Med Ethics 2000; 26 : 37-43.
40. Esparza J, Osmanov S. Current issues in HIV vaccine development. In: Narain JP, editor. AIDS in Asia - The challenge ahead. New Delhi: SAGE; 2004 p. 349-59.
41. Excler JL, Beyrer C. Human immunodeficiency virus vaccine development in developing countries. Are efficacy trials feasible? J Hum Virol 2000; 3 : 193-214.
42. Esparza J, Burke D. Epidemiological considerations in planning HIV preventive vaccine trials. AIDS 2001; 15 (Suppl 5) : S49-57.
43. Karita E. HIV incidence among discordant couples in Zambia and Rwanda. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th- September 1st 2004. (Abstract 33).
44. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001; 15 : 397-405.
45. Reynolds SJ, Risbud AR, Godbole SV, Shepherd ME, Joshi SN, Ghate MV, et al. Comparison of risk factors for incident sexually transmitted infections among men attending STI clinics in Pune, India. XV International AIDS Conference, Bangkok, Thailand, 11-16 July 2004. (Abstract ThPpC2097).
46. Girard MP, Mastro TD, Koff W. Human Immunodeficiency Virus. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 2004 p. 1219-58.
47. Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004; 17 : 17-26.
48. Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002; 76 : 5315-25.
49. Choopanya K, Tappero JW, Pitisuttithum P, Suntharasamai P, Kaewkungwal J, Vanichseni S, et al. Preliminary results of a phase III HIV vaccine efficacy trial among injecting drug users in Thailand. XV International AIDS Conference, Bangkok, Thailand, 11-16 July 2004. (Abstract ThOrA1427).
50. Srivastava IK, Ulmer JB, Barnett SW. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 2004; 3 (Suppl 1) : S33-52.
51. Fanales-Belasio E, Cafaro A, Cara A, Negri DR, Fiorelli V, Butto S, et al. HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol 2002; 21 : 599-610.
52. Horton H, Beckham C, Stucky J, Hallstrom J, Lee D, Ferrari G, et al. Induction of IL-2 secreting CD4+ T-cells capable of proliferation in seronegative subjects receiving the HIV-1 gp120/NefTat subunit vaccine. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th-September 1st 2004.(Abstract 54).
53. Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, et al. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173 : 330-9.
54. Salmon-Ceron D, Excler JL, Sicard D, Blanche P, Finkielstzjen L, Gluckman JC, et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995; 11 : 1479-86.
55. Gahery H, Silbermann B, Figueiredo S, Surenaud M, Bouillette M, Salmon D, et al. Specific immune responses induced by a new formulation of HIV lipopetide vaccine that combined HIV-1 CD8+ T-cell epitopes with a tetanus toxoid CD4+ T-cell epitope (ANRS VAC-12). AIDS Vaccine 2004, Lausanne, Switzerland, August 30th-September 1st 2004 (Abstract 52).
56. Hosmalin A, Andrieu M, Loing E, Desoutter JF, Hanau D, Gras-Masse H, et al. Lipopeptide presentation pathway in dendritic cells. Immunol Lett 2001; 79 : 97-100.
57. Gahery-Segard H, Pialoux G, Figueiredo S, Igea C, Surenaud M, Gaston J, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol 2003; 77 : 11220-31.
58. Harari H, Tapia G, Medjitna-Rais E, Poupon L, Frachette MJ, Bart PA, et al. Analysis of the immunogenicity of a pox-vector (NYVAC)-based vaccine expressing env, gag, pol and nef proteins of HIV-s subtype C. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th-September 1st 2004. [Abstract 51].
59. Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004; 3 (Suppl 1) : S89-97.
60. Garber D, Sumpter B, Barry A, McCausland M, Campbell D, McClure H, et al. Enhancing the immunogenicity and utility of MVA-based AIDS vaccines. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 15).
61. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004; 3 (Suppl 1) : S75-88.
62. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55 : 355-72.
63. Isaacs R. Impact of pre-existing immunity on the immunogenicity of Ad5-based vaccines. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 69).
64. Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002; 53 : 209-11.
65. Schnepp BC, Clark KR, Klemanski DL, Pacak CA and Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003; 77 : 3495-504.
66. Fouts TR, DeVico AL, Onyabe DY, Shata MT, Bagley KC, Lewis GK, et al. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 2003; 37 : 129-34.
67. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172 : 6290-7.
68. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004; 17 : 370-89.
69. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11 (Suppl A) : S127-37.
70. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998; 72 : 10180-8.
71. Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 2003; 77 : 13348-60.
72. Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 2004; 101 : 11088-93.
73. Guimaraes-Walker A, Mackie N, McMichael A, Weber J, McCormack S, Cebere I, et al. Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 55).
74. Joako W, Omosa G, Bhatt K, Matu L, Ogutu H, Wakasiaka S, et al. Safety and immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 56).
75. Kent SJ, Dale CJ, De Rose R, Stratov I, Purcell DF, Chea S, et al. Expanded immunogenicity and efficacy of single DNA and Fowlpoxvirus prime/boost vaccinees each expressing up to 5 shared genes of HIV-1 subtype A/E or SHI in macaques. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 61).
76. Salmon D, Gahery H, Silbermann B, Jackson A, Mazarin V, Souag N, et al. Safety and immunogenicity of HIV lipopeptides associated or not to a live HIV recombinant canarypox (ALVAC-HIV, vCP1452) in non-HIV-infected volunteers (ANRS VAC 10). AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 57).
77. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004; 78 : 11434-8.
78. Barouch D, Lemckert A, Havenga M, Custers J, Sumida S, Truitt D, et al. Immunogenicity of heterologous prime-boost vaccine regimens involving adenovirus serotypes 11 and 35. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 14).
79. Schultz AM, Connell MM, Koff WC, Wyand M, Anklesaria P, Johnson PR. Immunogenicity of two different AAV-based HIV vaccine candidates in non-human primates. AIDS Vaccine 2004, Lausanne, Switzerland, August 30th - September 1st 2004. (Abstract 16).
80. Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35 : 169-77.
81. Gaillard P, Fowler MG, Dabis F, Coovadia H, Van Der Horst C, Van Rompay K, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr 2004; 35 : 178-87.
82. Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 2004; 17 : 247-52.